Vol. 63 No. 3 (2017), ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

Vol. 63 No. 3 (2017)

NUMERICAL COEFFICIENT FOR ENDOMETRIAL CANCER INDIVIDUAL RISK EVALUATION IN POSTMENOPAUSAL WOMEN

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-3-461-465

Published 01.03.2017

Lev Bershteyn⁺⁻
Dmitriy Vasilev⁺⁻
Tatyana Poroshina⁺⁻
Igor Berlev⁺⁻

Lev Bershteyn

N.N. Petrov Research Institute of Oncology

Dmitriy Vasilev

N.N. Petrov Research Institute of Oncology

Tatyana Poroshina

N.N. Petrov Research Institute of Oncology

Igor Berlev

N.N. Petrov Research Institute of Oncology

##article.numberofdownloads## 27

##article.numberofviews## 104

PDF (Русский)

Keywords

ENDOMETRIAL CANCER
POSTMENOPAUSE
RISK
PERSONIFICATION
NUMERICAL COEFFICIENT

How to Cite

Bershteyn, L., Vasilev, D., Poroshina, T., & Berlev, I. (2017). NUMERICAL COEFFICIENT FOR ENDOMETRIAL CANCER INDIVIDUAL RISK EVALUATION IN POSTMENOPAUSAL WOMEN. Voprosy Onkologii, 63(3), 461–465. https://doi.org/10.37469/0507-3758-2017-63-3-461-465

Abstract

Increased frequency of endometrial cancer (EC) since the beginning of this century exceeds that of breast cancer and to a large extent can be attributed to dynamics of parameters, which characterize hormonal and metabolic status of ill women and molecular genetic landscape of transforming endometrium. During the past few years there are suggested several options for a personalized assessment of the risk of EC. The aim of this article is to propose and justify own version of this score with the idea of its further not only retrospective but also prospective testing both in relation to the risk of developing endometrial cancer as well as an additional marker helping to predict tumor response to treatment.

https://doi.org/10.37469/0507-3758-2017-63-3-461-465

##article.numberofdownloads## 27

##article.numberofviews## 104

PDF (Русский)

References

Балтрукова А.Н., Берлев И.В., Берштейн Л.М. Сравнительная оценка гормонально-метаболического статуса больных раком эндометрия за последние пять десятилетий // Журнал акушерства и женских болезней. - 2016. - Т. LXY(1). - С. 9-16.

Балтрукова А.Н., Берштейн Л.М., Берлев И.В. Сдвиги менструальной и репродуктивной функции у больных раком эндометрия за последние 50 лет // Вестн. СЗГМУ им. И.И. Мечникова. - 2016. - Т. 8 (4). - С. 75-80.

Берштейн Л.М. Гетерогенность ожирения и рак: потенциальная роль бурой жировой ткани // Вопр. онкол. - 2012. - Т. 58 (4). - С. 464-472.

Берштейн Л.М., Берлев И.В., Васильев Д.А. и др. Ожирение и особенности рака эндометрия: меняется ли что-нибудь с годами? // Вопр.онкол. -2015. - Т. 61 (4). - С. 575-579.

Бохман Я.В. Руководство по онкогинекологии. - Л.: Медицина, 1989. - 464 с.

Бохман Я.В., Костина Л.И. О патогенетических вариантах рака тела матки // Вопр. онкол. - 1972. - Т. 18 (2). - С. 18-24.

Унанян А.Л., Сидорова И.С., Коган Е.А., Бабурин Д.В. Прогнозирование рака тела матки у женщин с гиперпластическими процессами в пременопа-узальном возрасте // Акушерство, гинекология и репродукция. - 2012. - № 2. - С. 18-24.

Чернышова А.Л. Прогноз и особенности течения рака эндометрия на фоне метаболического синдрома. Автореф. дисс. докт. мед. наук. - Томск, 2009.

Amant F, Moerman P, Neven P et al. Endometrial cancer // Lancet. - 2005. - Vol. 366 (9484). - P. 491-505.

Aune D, Navarro Rosenblatt DA, Chan DS et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies // Ann Oncol. - 2015. - Vol. 26 (8). - P. 1635-1648.

Berstein L.M. Renovated (nondual) approach to endometrial cancer typing: endocrine and inflammatory issues // Future Oncol. - 2017. - Vol. 13 (2). - P. 109-112.

Berstein LM. Newborn macrosomy and cancer // Adv. Cancer Res. - 1988. - Vol. 50. - P. 231-278.

Berstein L.M., Poroshina T.E., Turkevich E.A. et al. Features of endometrial cancer in patients with ‘metabolically healthy' versus ‘standard' obesity: the decreasing frequency of metabolically healthy obesity // Future Sci. OA. - 2015. - Vol. 1 (4). - FSO68.

Boronow RC.Endometrial cancer: not a benign disease // Obstet. Gynecol. - 1976. - Vol. 47 (5). - P. 630-634.

Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers // Steroids. - 2015. - Vol. 99 (Pt A). - P. 8-10.

Cancer Research UK, http://www.cancerresearchuk. org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer, доступ: февраль 2017.

Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies // Lancet Oncol. - 2015. -Vol. 16 (9). - P. 1061-1070.

Esposito K, Chiodini P, Capuano A et al. Metabolic syndrome and endometrial cancer: a meta-analysis // Endocrine. - 2014. - Vol. 45 (1). - P. 28-36.

Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually // J. Natl. Cancer Inst. - 1989. - Vol. 81 (24). - P. 1879-1886.

Gail MH, Costantino JP, Bryant J et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer // J Natl Cancer Inst. - 1999. - Vol. 91 (21). - P. 1829-1846.

Grundker C, Gunthert AR, Emons G. Hormonal heterogeneity of endometrial cancer // Adv Exp Med Biol. - 2008. - Vol. 630. - P. 166-188.

Husing A., Dossus L., Ferrari P. et al. An epidemiological model for prediction of endometrial cancer risk in Europe // Eur. J. Epidemiol. - 2016. - Vol. 31 (1). - P. 51-60.

Kandoth C, Schultz N, Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma // Nature. - 2013. - Vol. 497 (7447). - P 67-73.

Kitson SJ, Evans DG, Crosbie EJ. Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model //Cancer Previo. Res. (Phila). - 2017. - Vol. 10 (1). - P. 1-13.

Lindemann K., Vatten L.J., Ellstr0m-Engh M., Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study // Br. J. Cancer. - 2008. -Vol. 98 (9). - P. 1582-1585.

Mehnert J.M., Panda A., Zhong H. et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer // J. Clin. Invest. - 2016. -Vol. 126 (6). - P. 2334-2340.

Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types // Lancet Oncol. - 2014. - Vol. 15 (7). - e268-278.

Pfeiffer RM, Park X Kreimer AR et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50y or older: derivation and validation from population-based cohort studies // PLoS Med. - 2013. -Vol. 10 (7). - e1001492.

Sivridis E., Giatromanolaki A. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma // J. Clin. Pathol. - 2004. - Vol. 57. - P. 840-844.

Sheikh MA, Althouse AD, Freese KF, et al. USA Endometrial Cancer Projections to 2030: should we be concerned? // Future Oncol. - 2014. - Vol. 10 (16). - P. 2561-2568.

Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach // Mod Pathol. - 2000. - Vol. 13 (3). - P. 295-308.

Tokmak A, Kokanali MK, Guzel AI et al. Polycystic ovary syndrome and risk of endometrial cancer: a mini-review // Asian Pac. J. Cancer Prev. - 2014. - Vol. 15 (17). - P. 7011-7014.

Tsilidis K.K., Kasimis J.C., Lopez D.S. et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies // BMJ. - 2015. - Vol. 350. -g7607.

Villavicencio A, Aguilar G, Acuna J. et al. The identification of two subgroups of obese women with differing endometrial proliferation levels: potential consequences in the development of endometrial cancer // Int. J. Obes. (Lond). - 2012. - Vol. 36 (7). - P. 1012-1015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Lev Bershteyn, Aleksandr Ivantsov, Aglaya Ievleva, A. Venina, I. Berlev, STEROID RECEPTOR PHENOTYPE, EXPRESSION OF HER-2/NEU, PD-1, PD-L1 AND LYMPHOCYTIC-MACROPHAGAL INFILTRATION OF ENDOMETRIAL CARCINOMAS: COMPARISON OF MODERN MOLECULAR BIOLOGICAL TYPES OF THE DISEASE (THE ROLE OF BODY MASS INDEX) , Voprosy onkologii : Vol. 66 No. 1 (2020)
Lev Bershteyn, Igor Berlev, Yelena Turkevich, A. Baltrukova, CHANGES IN ENDOMETRIAL CANCER CLINICAL AND MORPHOLOGICAL FEATURES DURING THE PAST HALF CENTURY , Voprosy onkologii : Vol. 63 No. 3 (2017)
Lev Bershteyn, Igor Berlev, Aglaya Ievleva, Aleksandr Ivantsov, A. Baltrukova, REMODELING OF THE VIEWS ON ENDOMENTRIAL CANCER: SIGNS AND REALITY , Voprosy onkologii : Vol. 64 No. 1 (2018)
Yelena Bakhidze, Anastasiya Malek, Alla Mikhetko, Mikhail Ivanov, Roman Samsonov, Igor Berlev, P. Arkhangelskaya, IMPROVEMENT OF CERVICAL CANCER SCREENING USING DETERMINATION OF MICRORNA IN CYTOLOGICAL PREPARATIONS , Voprosy onkologii : Vol. 63 No. 6 (2017)
Lev Bershteyn, Aglaya Ievleva, Tatyana Poroshina, Irina Kovalenko, COMPARATIVE FEATURES OF ENDOMETRIAL CANCER PATIENTS WITH A "STANDARD" AND "METABOLICALLY HEALTHY" OBESITY: GENETIC AND GENOTOXIC ASPECT , Voprosy onkologii : Vol. 63 No. 1 (2017)
Irina Kovalenko, Lev Bershteyn, COMPARATIVE HORMONE-ASSOCIATED AND CLINICAL-MORPHOLOGICAL FEATURES OF BREAST AND ENDOMETRIAL CANCER IN PATIENTS WITH AND WITHOUT DIABETES , Voprosy onkologii : Vol. 63 No. 5 (2017)

<< < 1 2 3